Assessing responses to cancer therapy using molecular imaging

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1766, Issue 2, 2006, Pages 242-261

  Neves, André A ^a   Brindle, Kevin M ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Angiogenesis; Apoptosis; Cancer therapy; Diagnostic imaging; Gene expression; Immunotherapy; Metabolism; MRI; Nuclear imaging; PET; Receptor imaging; Recurrence; Staging

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 125; 17 ALLYLAMINO 17 DEMETHOXYGELDANAMYCIN; 3' FLUOROTHYMIDINE; ALPHA FETOPROTEIN ANTIBODY TC 99M; ARCITUMOMAB TC 99M; CAPROMAB PENDETIDE IN 111; CARBON MONOXIDE C 11; CARBOPLATIN; CHOLINE C 11; CISPLATIN; COMBRETASTATIN A4 PHOSPHATE; ECHOVIST; FLUOROCHOLINE F 18; FLUORODEOXYGLUCOSE F 18; FLUOROETHILCHOLINE F 18; FLUOROURACIL; GADOFOSVESET; GADOXETIC ACID; IBRITUMOMAB TIUXETAN; IGOVOMAB; INDIMACIS I 125; INDOCYANINE GREEN; KI; METATRACE FDG; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; MONOCLONAL ANTIBODY B.72.3; MONOCLONAL ANTIBODY B.72.3 IN 111; NOFETUMOMAB TC 99M; OCTREOTIDE; ONCOSCINT CR; RADIOPHARMACEUTICAL AGENT; SUPERPARAMAGNETIC IRON OXIDE; TECNEMAB TC 99M; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERLUMA; VOTUMUMAB; VOTUMUMAB TC 99M; ANTINEOPLASTIC AGENT; TUMOR MARKER;

ADENOCARCINOMA; ANGIOGENESIS; APOPTOSIS; BRAIN TUMOR; BREAST CARCINOMA; CANCER; CANCER DIAGNOSIS; CANCER SURVIVAL; CANCER THERAPY; CELL DEATH; CELL PROLIFERATION; CLINICAL TRIAL; COLON ADENOCARCINOMA; COLON CANCER; COLORECTAL CARCINOMA; COMPUTER ASSISTED TOMOGRAPHY; DOSIMETRY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FIBROSARCOMA; GENE EXPRESSION; HODGKIN DISEASE; HUMAN; IMMUNOTHERAPY; IN VITRO STUDY; IN VIVO STUDY; LIVER CANCER; LUNG SMALL CELL CANCER; LYMPH NODE; METABOLISM; MIGRATION; MOLECULAR IMAGING; NEAR INFRARED SPECTROSCOPY; NEUROENDOCRINE TUMOR; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY ADENOCARCINOMA; PHOTON EMISSION TOMOGRAPHY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; RECURRENT DISEASE; REVIEW; SPECTROSCOPY; SURVIVAL RATE; TISSUE CULTURE CELL; TREATMENT RESPONSE; TUMOR CELL; BIOSYNTHESIS; DRUG EFFECT; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETIC PROCEDURES; GENETICS; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY);

ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOTHERAPY; MOLECULAR PROBE TECHNIQUES; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; TUMOR MARKERS, BIOLOGICAL;

EID: 33847267302     PISSN: 0304419X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbcan.2006.10.002     Document Type: Review

References (257)

1. Weissleder R., and Mahmood U. Molecular imaging. Radiology 219 (2001) 316-333
2. Miller A.B., Hoogstraten B., Staquet M., and Winkler A. Reporting results of cancer treatment. Cancer 47 (1981) 207-214
3. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., Verweij J., Van Glabbeke M., van Oosterom A.T., Christian M.C., and Gwyther S.G. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl. Cancer Inst. 92 (2000) 205-216
4. Hainsworth J.D., Sosman J.A., Spigel D.R., Edwards D.L., Baughman C., and Greco A. Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. J. Clin. Oncol. 23 (2005) 7889-7896
5. Weber W.A. Use of PET for monitoring cancer therapy and for predicting outcome. J. Nucl. Med. 46 (2005) 983-995
6. Aabakken L. Endoscopic tumor diagnosis and treatment. Endoscopy 35 (2003) 887-890
7. Hanahan D., and Weinberg R.A. The hallmarks of cancer. Cell 100 (2000) 57-70
8. Paez J.G., Janne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., Herman P., Kaye F.J., Lindeman N., Boggon T.J., Naoki K., Sasaki H., Fujii Y., Eck M.J., Sellers W.R., Johnson B.E., and Meyerson M. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304 (2004) 1497-1500
9. Herschman H.R. Molecular imaging: looking at problems, seeing solutions. Science 302 (2003) 605-608
10. Massoud T.F., and Gambhir S.S. Molecular imaging in living subjects: seeing fundamental biological processes in a new light. Genes Dev. 17 (2003) 545-580
11. Massoud T.F., Paulmurugan R., and Gambhir S.S. Molecular imaging of homodimeric protein-protein interactions in living subjects. FASEB J. 18 (2004) 1105-1107
12. Sullivan D.C., and Kelloff G. Seeing into cells. The promise of in vivo molecular imaging in oncology. EMBO Rep. 6 (2005) 292-296
13. Weissleder R. Molecular imaging: exploring the next frontier. Radiology 212 (1999) 609-614
14. Weissleder R. Scaling down imaging: molecular mapping of cancer in mice. Nat. Rev., Cancer 2 (2002) 11-18
15. Czarnota G.J., Kolios M.C., Abraham J., Portnoy M., Ottensmeyer F.P., Hunt J.W., and Sherar M.D. Ultrasound imaging of apoptosis: high-resolution non-invasive monitoring of programmed cell death in vitro, in situ and in vivo. Br. J. Cancer 81 (1999) 520-527
16. Jaffer F.A., and Weissleder R. Molecular imaging in the clinical arena. JAMA 293 (2005) 855-862
17. Kelloff G.J., Hoffman J.M., Johnson B., Scher H.I., Siegel B.A., Cheng E.Y., Cheson B.D., O'Shaughnessy J., Guyton K.Z., Mankoff D.A., Shankar L., Larson S.M., Sigman C.C., Schilsky R.L., and Sullivan D.C. Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clin. Cancer Res. 11 (2005) 2785-2808
18. von Schulthess G.K., Steinert H.C., and Hany T.F. Integrated PET/CT: current applications and future directions. Radiology 238 (2006) 405-422
19. Rosenbaum S.J., Lind T., Antoch G., and Bockisch A. False-positive FDG PET uptake-The role of PET/CT. Eur. Radiol. 16 (2006) 1054-1065
20. Ell P.J. The contribution of PET/CT to improved patient management. Br. J. Radiol. 79 (2006) 32-36
21. Avison M.J., Hetherington H.P., and Shulman R.G. Applications of NMR to studies of tissue metabolism. Annu. Rev. Biophys. Biophys. Chem. 15 (1986) 377-402
22. Gillies R.J., and Morse D.L. In vivo magnetic resonance spectroscopy in cancer. Annu. Rev. Biomed. Eng. 7 (2005) 287-326
23. Radda G.K. Control, bioenergetics, and adaptation in health and disease: noninvasive biochemistry from nuclear magnetic resonance. FASEB J. 6 (1992) 3032-3038
24. Ntziachristos V., Bremer C., and Weissleder R. Fluorescence imaging with near-infrared light: new technological advances that enable in vivo molecular imaging. Eur. Radiol. 13 (2003) 195-208
25. Kelly K., Alencar H., Funovics M., Mahmood U., and Weissleder R. Detection of invasive colon cancer using a novel, targeted, library-derived fluorescent peptide. Cancer Res. 64 (2004) 6247-6251
26. Jemal A., Siegel R., Ward E., Murray T., Xu J., Smigal C., and Thun M.J. Cancer statistics, 2006. C.A. Cancer J. Clin. 56 (2006) 106-130
27. Gatenby R.A., and Gillies R.J. Why do cancers have high aerobic glycolysis?. Nat. Rev., Cancer 4 (2004) 891-899
28. Mamede M., Higashi T., Kitaichi M., Ishizu K., Ishimori T., Nakamoto Y., Yanagihara K., Li M., Tanaka F., Wada H., Manabe T., and Saga T. [18F]FDG uptake and PCNA, Glut-1, and Hexokinase-II expressions in cancers and inflammatory lesions of the lung. Neoplasia 7 (2005) 369-379
29. Tohma T., Okazumi S., Makino H., Cho A., Mochiduki R., Shuto K., Kudo H., Matsubara K., Gunji H., and Ochiai T. Relationship between glucose transporter, hexokinase and FDG-PET in esophageal cancer. Hepatogastroenterology 52 (2005) 486-490
30. Zhao S., Kuge Y., Mochizuki T., Takahashi T., Nakada K., Sato M., Takei T., and Tamaki N. Biologic correlates of intratumoral heterogeneity in 18F-FDG distribution with regional expression of glucose transporters and hexokinase-II in experimental tumor. J. Nucl. Med. 46 (2005) 675-682
31. Phelps M.E. PET: the merging of biology and imaging into molecular imaging. J. Nucl. Med. 41 (2000) 661-681
32. Rohren E.M., Turkington T.G., and Coleman R.E. Clinical applications of PET in oncology. Radiology 231 (2004) 305-332
33. Phelps M.E., and Mazziotta J.C. Positron emission tomography: human brain function and biochemistry. Science 228 (1985) 799-809
34. Schwaiger M., Ziegler S., and Nekolla S.G. PET/CT: challenge for nuclear cardiology. J. Nucl. Med. 46 (2005) 1664-1678
35. Zhuang H., Yu J.Q., and Alavi A. Applications of fluorodeoxyglucose-PET imaging in the detection of infection and inflammation and other benign disorders. Radiol. Clin. North Am. 43 (2005) 121-134
36. Shields A.F. Positron emission tomography measurement of tumor metabolism and growth: its expanding role in oncology. Mol. Imaging Biol. 8 (2006) 141-150
37. Czernin J., and Phelps M.E. Positron emission tomography scanning: current and future applications. Annu. Rev. Med. 53 (2002) 89-112
38. Gambhir S.S., Czernin J., Schwimmer J., Silverman D.H., Coleman R.E., and Phelps M.E. A tabulated summary of the FDG PET literature. J. Nucl. Med. 42 (2001) 1S-93S
39. Czernin J., Weber W.A., and Herschman H.R. Molecular imaging in the development of cancer therapeutics. Annu. Rev. Med. 57 (2006) 99-118
40. Stahl A., Ott K., Schwaiger M., and Weber W.A. Comparison of different SUV-based methods for monitoring cytotoxic therapy with FDG PET. Eur. J. Nucl. Med. Mol. Imaging 31 (2004) 1471-1478
41. Diederichs C.G., Staib L., Glatting G., Beger H.G., and Reske S.N. FDG PET: elevated plasma glucose reduces both uptake and detection rate of pancreatic malignancies. J. Nucl. Med. 39 (1998) 1030-1033
42. Thie J.A. Understanding the standardized uptake value, its methods, and implications for usage. J. Nucl. Med. 45 (2004) 1431-1434
43. Quon A., and Gambhir S.S. FDG-PET and beyond: molecular breast cancer imaging. J. Clin. Oncol. 23 (2005) 1664-1673
44. Schelling M., Avril N., Nahrig J., Kuhn W., Romer W., Sattler D., Werner M., Dose J., Janicke F., Graeff H., and Schwaiger M. Positron emission tomography using [(18)F]Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J. Clin. Oncol. 18 (2000) 1689-1695
45. Schwimmer J., Essner R., Patel A., Jahan S.A., Shepherd J.E., Park K., Phelps M.E., Czernin J., and Gambhir S.S. A review of the literature for whole-body FDG PET in the management of patients with melanoma. Q. J. Nucl. Med. 44 (2000) 153-167
46. Ott K., Fink U., Becker K., Stahl A., Dittler H.J., Busch R., Stein H., Lordick F., Link T., Schwaiger M., Siewert J.R., and Weber W.A. Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial. J. Clin. Oncol. 21 (2003) 4604-4610
47. Pottgen C., Levegrun S., Theegarten D., Marnitz S., Grehl S., Pink R., Eberhardt W., Stamatis G., Gauler T., Antoch G., Bockisch A., and Stuschke M. Value of 18F-fluoro-2-deoxy-d-glucose-positron emission tomography/computed tomography in non-small-cell lung cancer for prediction of pathologic response and times to relapse after neoadjuvant chemoradiotherapy. Clin. Cancer Res. 12 (2006) 97-106
48. Weber W.A., Petersen V., Schmidt B., Tyndale-Hines L., Link T., Peschel C., and Schwaiger M. Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. J. Clin. Oncol. 21 (2003) 2651-2657
49. Filmont J.E., Czernin J., Yap C., Silverman D.H., Quon A., Phelps M.E., and Emmanouilides C. Value of F-18 fluorodeoxyglucose positron emission tomography for predicting the clinical outcome of patients with aggressive lymphoma prior to and after autologous stem-cell transplantation. Chest 124 (2003) 608-613
50. Haioun C., Itti E., Rahmouni A., Brice P., Rain J.D., Belhadj K., Gaulard P., Garderet L., Lepage E., Reyes F., and Meignan M. [18F]fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood 106 (2005) 1376-1381
51. Hutchings M., Loft A., Hansen M., Pedersen L.M., Buhl T., Jurlander J., Buus S., Keiding S., D'Amore F., Boesen A.M., Berthelsen A.K., and Specht L. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 107 (2006) 52-59
52. Spaepen K., Stroobants S., Dupont P., Van Steenweghen S., Thomas J., Vandenberghe P., Vanuytsel L., Bormans G., Balzarini J., De Wolf-Peeters C., Mortelmans L., and Verhoef G. Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods?. J. Clin. Oncol. 19 (2001) 414-419
53. Xue F., Lin L., Dehdashti F., Miller T.R., Siegel B.A., and Grigsby P.W. F-18 fluorodeoxyglucose uptake in primary cervical cancer as an indicator of prognosis after radiation therapy. Gynecol. Oncol. 101 (2006) 147-151
54. Denecke T., Rau B., Hoffmann K.T., Hildebrandt B., Ruf J., Gutberlet M., Hunerbein M., Felix R., Wust P., and Amthauer H. Comparison of CT, MRI and FDG-PET in response prediction of patients with locally advanced rectal cancer after multimodal preoperative therapy: is there a benefit in using functional imaging?. Eur. Radiol. 15 (2005) 1658-1666
55. Valk P.E., Abella-Columna E., Haseman M.K., Pounds T.R., Tesar R.D., Myers R.W., Greiss H.B., and Hofer G.A. Whole-body PET imaging with [18F]fluorodeoxyglucose in management of recurrent colorectal cancer. Arch. Surg. 134 (1999) 503-511 (discussion 511-3)
56. Herholz K., and Heiss W.D. Positron emission tomography in clinical neurology. Mol. Imaging Biol. 6 (2004) 239-269
57. Porceddu S.V., Jarmolowski E., Hicks R.J., Ware R., Weih L., Rischin D., Corry J., and Peters L.J. Utility of positron emission tomography for the detection of disease in residual neck nodes after (chemo)radiotherapy in head and neck cancer. Head Neck 27 (2005) 175-181
58. Morris M.J., Akhurst T., Larson S.M., Ditullio M., Chu E., Siedlecki K., Verbel D., Heller G., Kelly W.K., Slovin S., Schwartz L., and Scher H.I. Fluorodeoxyglucose positron emission tomography as an outcome measure for castrate metastatic prostate cancer treated with antimicrotubule chemotherapy. Clin. Cancer Res. 11 (2005) 3210-3216
59. M.J. Forshaw, J.A. Gossage, R.C. Mason, Neoadjuvant chemotherapy for oesophageal cancer: the need for accurate response prediction and evaluation, Surgeon 3 (2005), 373-382, 422.
60. Weber W.A., Ott K., Becker K., Dittler H.J., Helmberger H., Avril N.E., Meisetschlager G., Busch R., Siewert J.R., Schwaiger M., and Fink U. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J. Clin. Oncol. 19 (2001) 3058-3065
61. Wieder H.A., Brucher B.L., Zimmermann F., Becker K., Lordick F., Beer A., Schwaiger M., Fink U., Siewert J.R., Stein H.J., and Weber W.A. Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment. J. Clin. Oncol. 22 (2004) 900-908
62. Westerterp M., van Westreenen H.L., Reitsma J.B., Hoekstra O.S., Stoker J., Fockens P., Jager P.L., Van Eck-Smit B.L., Plukker J.T., van Lanschot J.J., and Sloof G.W. Esophageal cancer: CT, endoscopic US, and FDG PET for assessment of response to neoadjuvant therapy-systematic review. Radiology 236 (2005) 841-851
63. Schwartz J.L., Tamura Y., Jordan R., Grierson J.R., and Krohn K.A. Monitoring tumor cell proliferation by targeting DNA synthetic processes with thymidine and thymidine analogs. J. Nucl. Med. 44 (2003) 2027-2032
64. Shields A.F., Grierson J.R., Dohmen B.M., Machulla H.J., Stayanoff J.C., Lawhorn-Crews J.M., Obradovich J.E., Muzik O., and Mangner T.J. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat. Med. 4 (1998) 1334-1336
65. Chen W., Cloughesy T., Kamdar N., Satyamurthy N., Bergsneider M., Liau L., Mischel P., Czernin J., Phelps M.E., and Silverman D.H. Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG. J. Nucl. Med. 46 (2005) 945-952
66. Barthel H., Cleij M.C., Collingridge D.R., Hutchinson O.C., Osman S., He Q., Luthra S.K., Brady F., Price P.M., and Aboagye E.O. 3′-deoxy-3′-[18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography. Cancer Res. 63 (2003) 3791-3798
67. Buck A.K., Halter G., Schirrmeister H., Kotzerke J., Wurziger I., Glatting G., Mattfeldt T., Neumaier B., Reske S.N., and Hetzel M. Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG. J. Nucl. Med. 44 (2003) 1426-1431
68. Juweid M.E., and Cheson B.D. Positron-emission tomography and assessment of cancer therapy. N. Engl. J. Med. 354 (2006) 496-507
69. van Waarde A., Cobben D.C., Suurmeijer A.J., Maas B., Vaalburg W., de Vries E.F., Jager P.L., Hoekstra H.J., and Elsinga P.H. Selectivity of 18F-FLT and 18F-FDG for differentiating tumor from inflammation in a rodent model. J. Nucl. Med. 45 (2004) 695-700
70. Kwee S.A., Coel M.N., Lim J., and Ko J.P. Prostate cancer localization with 18fluorine fluorocholine positron emission tomography. J. Urol. 173 (2005) 252-255
71. Price D.T., Coleman R.E., Liao R.P., Robertson C.N., Polascik T.J., and DeGrado T.R. Comparison of [18 F]fluorocholine and [18 F]fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer. J. Urol. 168 (2002) 273-280
72. Kwee S.A., Coel M.N., Lim J., and Ko J.P. Combined use of F-18 fluorocholine positron emission tomography and magnetic resonance spectroscopy for brain tumor evaluation. J. Neuroimaging 14 (2004) 285-289
73. Hara T., Kosaka N., and Kishi H. Development of (18)F-fluoroethylcholine for cancer imaging with PET: synthesis, biochemistry, and prostate cancer imaging. J. Nucl. Med. 43 (2002) 187-199
74. Gillies R.J., Bhujwalla Z.M., Evelhoch J., Garwood M., Neeman M., Robinson S.P., Sotak C.H., and Van Der Sanden B. Applications of magnetic resonance in model systems: tumor biology and physiology. Neoplasia 2 (2000) 139-151
75. Glunde K., Jie C., and Bhujwalla Z.M. Molecular causes of the aberrant choline phospholipid metabolism in breast cancer. Cancer Res. 64 (2004) 4270-4276
76. Leach M.O., Verrill M., Glaholm J., Smith T.A., Collins D.J., Payne G.S., Sharp J.C., Ronen S.M., McCready V.R., Powles T.J., and Smith I.E. Measurements of human breast cancer using magnetic resonance spectroscopy: a review of clinical measurements and a report of localized 31P measurements of response to treatment. NMR Biomed. 11 (1998) 314-340
77. Roebuck J.R., Cecil K.M., Schnall M.D., and Lenkinski R.E. Human breast lesions: characterization with proton MR spectroscopy. Radiology 209 (1998) 269-275
78. Katz-Brull R., Lavin P.T., and Lenkinski R.E. Clinical utility of proton magnetic resonance spectroscopy in characterizing breast lesions. J. Natl. Cancer Inst. 94 (2002) 1197-1203
79. Kurhanewicz J., Swanson M.G., Nelson S.J., and Vigneron D.B. Combined magnetic resonance imaging and spectroscopic imaging approach to molecular imaging of prostate cancer. J. Magn. Reson. Imaging 16 (2002) 451-463
80. Chung Y.L., Troy H., Banerji U., Jackson L.E., Walton M.I., Stubbs M., Griffiths J.R., Judson I.R., Leach M.O., Workman P., and Ronen S.M. Magnetic resonance spectroscopic pharmacodynamic markers of the heat shock protein 90 inhibitor 17-allylamino,17-demethoxygeldanamycin (17AAG) in human colon cancer models. J. Natl. Cancer Inst. 95 (2003) 1624-1633
81. Al-Saffar N.M., Troy H., Ramirez de Molina A., Jackson L.E., Madhu B., Griffiths J.R., Leach M.O., Workman P., Lacal J.C., Judson I.R., and Chung Y.L. Noninvasive magnetic resonance spectroscopic pharmacodynamic markers of the choline kinase inhibitor MN58b in human carcinoma models. Cancer Res. 66 (2006) 427-434
82. Beloueche-Babari M., Jackson L.E., Al-Saffar N.M., Workman P., Leach M.O., and Ronen S.M. Magnetic resonance spectroscopy monitoring of mitogen-activated protein kinase signaling inhibition. Cancer Res. 65 (2005) 3356-3363
83. Ardenkjaer-Larsen J.H., Fridlund B., Gram A., Hansson G., Hansson L., Lerche M.H., Servin R., Thaning M., and Golman K. Increase in signal-to-noise ratio of > 10,000 times in liquid-state NMR. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 10158-10163
84. Golman K., Ardenkjaer-Larsen J.H., Petersson J.S., Mansson S., and Leunbach I. Molecular imaging with endogenous substances. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 10435-10439
85. Mansson S., Johansson E., Magnusson P., Chai C.M., Hansson G., Petersson J.S., Stahlberg F., and Golman K. 13C imaging-a new diagnostic platform. Eur. Radiol. 16 (2006) 57-67
86. Olsson L.E., Chai C.M., Axelsson O., Karlsson M., Golman K., and Petersson J.S. MR coronary angiography in pigs with intraarterial injections of a hyperpolarized 13C substance. Magn. Reson. Med. 55 (2006) 731-737
87. Hanahan D. Signaling vascular morphogenesis and maintenance. Science 277 (1997) 48-50
88. Bergers G., and Benjamin L.E. Tumorigenesis and the angiogenic switch. Nat. Rev., Cancer 3 (2003) 401-410
89. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. 1 (1995) 27-31
90. Carmeliet P., and Jain R.K. Angiogenesis in cancer and other diseases. Nature 407 (2000) 249-257
91. Michor F., Nowak M.A., and Iwasa Y. Evolution of resistance to cancer therapy. Curr. Pharm. Des. 12 (2006) 261-271
92. Los M., and Voest E.E. The potential role of antivascular therapy in the adjuvant and neoadjuvant treatment of cancer. Semin. Oncol. 28 (2001) 93-105
93. Folkman J. Angiogenesis. Annu. Rev. Med. 57 (2006) 1-18
94. Ahmed S.I., Thomas A.L., and Steward W.P. Vascular endothelial growth factor (VEGF) inhibition by small molecules. J. Chemother. 16 Suppl. 4 (2004) 59-63
95. Gaya A.M., and Rustin G.J. Vascular disrupting agents: a new class of drug in cancer therapy. Clin. Oncol. (R Coll. Radiol.) 17 (2005) 277-290
96. Bilenker J.H., Flaherty K.T., Rosen M., Davis L., Gallagher M., Stevenson J.P., Sun W., Vaughn D., Giantonio B., Zimmer R., Schnall M., and O'Dwyer P.J. Phase I trial of combretastatin a-4 phosphate with carboplatin. Clin. Cancer Res. 11 (2005) 1527-1533
97. O'Hanlon L.H. Taking down tumors: vascular disrupting agents entering clinical trials. J. Natl. Cancer Inst. 97 (2005) 1244-1245
98. West C.M., and Price P. Combretastatin A4 phosphate. Anti-cancer Drugs 15 (2004) 179-187
99. Kabbinavar F.F., Schulz J., McCleod M., Patel T., Hamm J.T., Hecht J.R., Mass R., Perrou B., Nelson B., and Novotny W.F. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J. Clin. Oncol. 23 (2005) 3697-3705
100. Dark G.G., Hill S.A., Prise V.E., Tozer G.M., Pettit G.R., and Chaplin D.J. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res. 57 (1997) 1829-1834
101. Beauregard D.A., Thelwall P.E., Chaplin D.J., Hill S.A., Adams G.E., and Brindle K.M. Magnetic resonance imaging and spectroscopy of combretastatin A4 prodrug-induced disruption of tumour perfusion and energetic status. Br. J. Cancer 77 (1998) 1761-1767
102. Beauregard D.A., Hill S.A., Chaplin D.J., and Brindle K.M. The susceptibility of tumors to the antivascular drug combretastatin A4 phosphate correlates with vascular permeability. Cancer Res. 61 (2001) 6811-6815
103. Brasch R., and Turetschek K. MRI characterization of tumors and grading angiogenesis using macromolecular contrast media: status report. Eur. J. Radiol. 34 (2000) 148-155
104. Jordan B.F., Runquist M., Raghunand N., Baker A., Williams R., Kirkpatrick L., Powis G., and Gillies R.J. Dynamic contrast-enhanced and diffusion MRI show rapid and dramatic changes in tumor microenvironment in response to inhibition of HIF-1alpha using PX-478. Neoplasia 7 (2005) 475-485
105. Rustin G.J., Galbraith S.M., Anderson H., Stratford M., Folkes L.K., Sena L., Gumbrell L., and Price P.M. Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results. J. Clin. Oncol. 21 (2003) 2815-2822
106. Stevenson J.P., Rosen M., Sun W., Gallagher M., Haller D.G., Vaughn D., Giantonio B., Zimmer R., Petros W.P., Stratford M., Chaplin D., Young S.L., Schnall M., and O'Dwyer P.J. Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow. J. Clin. Oncol. 21 (2003) 4428-4438
107. Leach M.O., Brindle K.M., Evelhoch J.L., Griffiths J.R., Horsman M.R., Jackson A., Jayson G.C., Judson I.R., Knopp M.V., Maxwell R.J., McIntyre D., Padhani A.R., Price P., Rathbone R., Rustin G.J., Tofts P.S., Tozer G.M., Vennart W., Waterton J.C., Williams S.R., and Workman P. The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations. Br. J. Cancer 92 (2005) 1599-1610
108. Laking G.R., and Price P.M. Positron emission tomographic imaging of angiogenesis and vascular function. Br. J. Radiol. 76 Spec No 1 (2003) S50-S59
109. McDonald D.M., and Choyke P.L. Imaging of angiogenesis: from microscope to clinic. Nat. Med. 9 (2003) 713-725
110. Neeman M., Dafni H., Bukhari O., Braun R.D., and Dewhirst M.W. In vivo BOLD contrast MRI mapping of subcutaneous vascular function and maturation: validation by intravital microscopy. Magn. Reson. Med. 45 (2001) 887-898
111. Jin H., and Varner J. Integrins: roles in cancer development and as treatment targets. Br. J. Cancer 90 (2004) 561-565
112. Sipkins D.A., Cheresh D.A., Kazemi M.R., Nevin L.M., Bednarski M.D., and Li K.C. Detection of tumor angiogenesis in vivo by alphaVbeta3-targeted magnetic resonance imaging. Nat. Med. 4 (1998) 623-626
113. Mulder W.J., Strijkers G.J., Habets J.W., Bleeker E.J., van der Schaft D.W., Storm G., Koning G.A., Griffioen A.W., and Nicolay K. MR molecular imaging and fluorescence microscopy for identification of activated tumor endothelium using a bimodal lipidic nanoparticle. FASEB J. 19 (2005) 2008-2010
114. Schmieder A.H., Winter P.M., Caruthers S.D., Harris T.D., Williams T.A., Allen J.S., Lacy E.K., Zhang H., Scott M.J., Hu G., Robertson J.D., Wickline S.A., and Lanza G.M. Molecular MR imaging of melanoma angiogenesis with alphanubeta3-targeted paramagnetic nanoparticles. Magn. Reson. Med. 53 (2005) 621-627
115. Winter P.M., Caruthers S.D., Kassner A., Harris T.D., Chinen L.K., Allen J.S., Lacy E.K., Zhang H., Robertson J.D., Wickline S.A., and Lanza G.M. Molecular imaging of angiogenesis in nascent Vx-2 rabbit tumors using a novel alpha(nu)beta3-targeted nanoparticle and 1.5 tesla magnetic resonance imaging. Cancer Res. 63 (2003) 5838-5843
116. Haubner R., Wester H.J., Weber W.A., Mang C., Ziegler S.I., Goodman S.L., Senekowitsch-Schmidtke R., Kessler H., and Schwaiger M. Noninvasive imaging of alpha(v)beta3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res. 61 (2001) 1781-1785
117. Miller J.C., Pien H.H., Sahani D., Sorensen A.G., and Thrall J.H. Imaging angiogenesis: applications and potential for drug development. J. Natl. Cancer Inst. 97 (2005) 172-187
118. Jaiswal J.K., Mattoussi H., Mauro J.M., and Simon S.M. Long-term multiple color imaging of live cells using quantum dot bioconjugates. Nat. Biotechnol. 21 (2003) 47-51
119. Medintz I.L., Uyeda H.T., Goldman E.R., and Mattoussi H. Quantum dot bioconjugates for imaging, labelling and sensing. Nat. Mater. 4 (2005) 435-446
120. Michalet X., Pinaud F.F., Bentolila L.A., Tsay J.M., Doose S., Li J.J., Sundaresan G., Wu A.M., Gambhir S.S., and Weiss S. Quantum dots for live cells, in vivo imaging, and diagnostics. Science 307 (2005) 538-544
121. Ballou B., Ernst L.A., and Waggoner A.S. Fluorescence imaging of tumors in vivo. Curr. Med. Chem. 12 (2005) 795-805
122. Cai W., Shin D.W., Chen K., Gheysens O., Cao Q., Wang S.X., Gambhir S.S., and Chen X. Peptide-labeled near-infrared quantum dots for imaging tumor vasculature in living subjects. Nano Lett. 6 (2006) 669-676
123. Roberts R.L., and Lin P.C. Structural and functional optical imaging of angiogenesis in animal models. Methods Enzymol. 386 (2004) 105-122
124. Bergman J.J. Latest developments in the endoscopic management of gastroesophageal reflux disease and Barrett's esophagus: an overview of the year's literature. Endoscopy 38 (2006) 122-132
125. DaCosta R.S., Wilson B.C., and Marcon N.E. Optical techniques for the endoscopic detection of dysplastic colonic lesions. Curr. Opin. Gastroenterol. 21 (2005) 70-79
126. Belzile J.P., Choudhury S.A., Cournoyer D., and Chow T.Y. Targeting DNA repair proteins: a promising avenue for cancer gene therapy. Curr. Gene Ther. 6 (2006) 111-123
127. Shah K., Jacobs A., Breakefield X.O., and Weissleder R. Molecular imaging of gene therapy for cancer. Gene Ther. 11 (2004) 1175-1187
128. Gambhir S.S., Barrio J.R., Phelps M.E., Iyer M., Namavari M., Satyamurthy N., Wu L., Green L.A., Bauer E., MacLaren D.C., Nguyen K., Berk A.J., Cherry S.R., and Herschman H.R. Imaging adenoviral-directed reporter gene expression in living animals with positron emission tomography. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 2333-2338
129. Tjuvajev J.G., Finn R., Watanabe K., Joshi R., Oku T., Kennedy J., Beattie B., Koutcher J., Larson S., and Blasberg R.G. Noninvasive imaging of herpes virus thymidine kinase gene transfer and expression: a potential method for monitoring clinical gene therapy. Cancer Res. 56 (1996) 4087-4095
130. Contag P.R., Olomu I.N., Stevenson D.K., and Contag C.H. Bioluminescent indicators in living mammals. Nat. Med. 4 (1998) 245-247
131. Genove G., DeMarco U., Xu H., Goins W.F., and Ahrens E.T. A new transgene reporter for in vivo magnetic resonance imaging. Nat. Med. 11 (2005) 450-454
132. Louie A.Y., Huber M.M., Ahrens E.T., Rothbacher U., Moats R., Jacobs R.E., Fraser S.E., and Meade T.J. In vivo visualization of gene expression using magnetic resonance imaging. Nat. Biotechnol. 18 (2000) 321-325
133. Weissleder R., Moore A., Mahmood U., Bhorade R., Benveniste H., Chiocca E.A., and Basilion J.P. In vivo magnetic resonance imaging of transgene expression. Nat. Med. 6 (2000) 351-355
134. Gross S., and Piwnica-Worms D. Spying on cancer: molecular imaging in vivo with genetically encoded reporters. Cancer Cell 7 (2005) 5-15
135. Rogers B.E., Zinn K.R., and Buchsbaum D.J. Gene transfer strategies for improving radiolabeled peptide imaging and therapy. Q. J. Nucl. Med. 44 (2000) 208-223
136. Ellenberg J., Lippincott-Schwartz J., and Presley J.F. Dual-colour imaging with GFP variants. Trends Cell Biol. 9 (1999) 52-56
137. Misteli T., and Spector D.L. Applications of the green fluorescent protein in cell biology and biotechnology. Nat. Biotechnol. 15 (1997) 961-964
138. Tsien R.Y. The green fluorescent protein. Annu. Rev. Biochem. 67 (1998) 509-544
139. Le L.P., Le H.N., Dmitriev I.P., Davydova J.G., Gavrikova T., Yamamoto S., Curiel D.T., and Yamamoto M. Dynamic monitoring of oncolytic adenovirus in vivo by genetic capsid labeling. J. Natl. Cancer Inst. 98 (2006) 203-214
140. Mayer-Kuckuk P., Banerjee D., Malhotra S., Doubrovin M., Iwamoto M., Akhurst T., Balatoni J., Bornmann W., Finn R., Larson S., Fong Y., Gelovani Tjuvajev J., Blasberg R., and Bertino J.R. Cells exposed to antifolates show increased cellular levels of proteins fused to dihydrofolate reductase: a method to modulate gene expression. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 3400-3405
141. Mansfield J.R., Gossage K.W., Hoyt C.C., and Levenson R.M. Autofluorescence removal, multiplexing, and automated analysis methods for in-vivo fluorescence imaging. J. Biomed. Opt. 10 (2005) 41207
142. Bhaumik S., and Gambhir S.S. Optical imaging of Renilla luciferase reporter gene expression in living mice. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 377-382
143. Tannous B., Kim D., and Weissleder R. Novel luciferases for in vitro and in vivo imaging. Mol. Imaging 3 (2004) 227
144. Pichler A., Prior J.L., and Piwnica-Worms D. Imaging reversal of multidrug resistance in living mice with bioluminescence: MDR1 P-glycoprotein transports coelenterazine. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 1702-1707
145. Rehemtulla A., Stegman L.D., Cardozo S.J., Gupta S., Hall D.E., Contag C.H., and Ross B.D. Rapid and quantitative assessment of cancer treatment response using in vivo bioluminescence imaging. Neoplasia 2 (2000) 491-495
146. Jacobs A., Voges J., Reszka R., Lercher M., Gossmann A., Kracht L., Kaestle C., Wagner R., Wienhard K., and Heiss W.D. Positron-emission tomography of vector-mediated gene expression in gene therapy for gliomas. Lancet 358 (2001) 727-729
147. Lichtenstein D.L., and Wold W.S. Experimental infections of humans with wild-type adenoviruses and with replication-competent adenovirus vectors: replication, safety, and transmission. Cancer Gene Ther. 11 (2004) 819-829
148. Yaghoubi S.S., Barrio J.R., Namavari M., Satyamurthy N., Phelps M.E., Herschman H.R., and Gambhir S.S. Imaging progress of herpes simplex virus type 1 thymidine kinase suicide gene therapy in living subjects with positron emission tomography. Cancer Gene Ther. 12 (2005) 329-339
149. Kagaya T., Nakamoto Y., Sakai Y., Tsuchiyama T., Yagita H., Mukaida N., and Kaneko S. Monocyte chemoattractant protein-1 gene delivery enhances antitumor effects of herpes simplex virus thymidine kinase/ganciclovir system in a model of colon cancer. Cancer Gene Ther. 13 (2006) 357-366
150. Everts B., and van der Poel H.G. Replication-selective oncolytic viruses in the treatment of cancer. Cancer Gene Ther. 12 (2005) 141-161
151. Gambhir S.S., Bauer E., Black M.E., Liang Q., Kokoris M.S., Barrio J.R., Iyer M., Namavari M., Phelps M.E., and Herschman H.R. A mutant herpes simplex virus type 1 thymidine kinase reporter gene shows improved sensitivity for imaging reporter gene expression with positron emission tomography. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 2785-2790
152. Varghese S., and Rabkin S.D. Oncolytic herpes simplex virus vectors for cancer virotherapy. Cancer Gene Ther. 9 (2002) 967-978
153. Gambhir S.S., Barrio J.R., Wu L., Iyer M., Namavari M., Satyamurthy N., Bauer E., Parrish C., MacLaren D.C., Borghei A.R., Green L.A., Sharfstein S., Berk A.J., Cherry S.R., Phelps M.E., and Herschman H.R. Imaging of adenoviral-directed herpes simplex virus type 1 thymidine kinase reporter gene expression in mice with radiolabeled ganciclovir. J. Nucl. Med. 39 (1998) 2003-2011
154. Iyer M., Barrio J.R., Namavari M., Bauer E., Satyamurthy N., Nguyen K., Toyokuni T., Phelps M.E., Herschman H.R., and Gambhir S.S. 8-[18F]Fluoropenciclovir: an improved reporter probe for imaging HSV1-tk reporter gene expression in vivo using PET. J. Nucl. Med. 42 (2001) 96-105
155. Serganova I., and Blasberg R. Reporter gene imaging: potential impact on therapy. Nucl. Med. Biol. 32 (2005) 763-780
156. Grotzinger C., and Wiedenmann B. Somatostatin receptor targeting for tumor imaging and therapy. Ann. N. Y. Acad. Sci. 1014 (2004) 258-264
157. Rogers B.E., Parry J.J., Andrews R., Cordopatis P., Nock B.A., and Maina T. MicroPET imaging of gene transfer with a somatostatin receptor-based reporter gene and (94m)Tc-Demotate 1. J. Nucl. Med. 46 (2005) 1889-1897
158. Groot-Wassink T., Barthel H., Lemoine N.R., and Vassaux G. Sodium iodide symporter: a new strategy to target cancer?. Lancet 361 (2003) 1905-1906
159. Groot-Wassink T., Aboagye E.O., Glaser M., Lemoine N.R., and Vassaux G. Adenovirus biodistribution and noninvasive imaging of gene expression in vivo by positron emission tomography using human sodium/iodide symporter as reporter gene. Hum. Gene Ther. 13 (2002) 1723-1735
160. Groot-Wassink T., Aboagye E.O., Wang Y.H., Lemoine N.R., Reader A.J., and Vassaux G. Quantitative imaging of Na/I symporter transgene expression using positron emission tomography in the living animal. Molec. Ther. 9 (2004) 436-442
161. Lane D.P. Cancer. p53, guardian of the genome. Nature 358 (1992) 15-16
162. Doubrovin M., Ponomarev V., Beresten T., Balatoni J., Bornmann W., Finn R., Humm J., Larson S., Sadelain M., Blasberg R., and Gelovani Tjuvajev J. Imaging transcriptional regulation of p53-dependent genes with positron emission tomography in vivo. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 9300-9305
163. Paroo Z., and Corey D.R. Imaging gene expression using oligonucleotides and peptide nucleic acids. J. Cell. Biochem. 90 (2003) 437-442
164. Younes C.K., Boisgard R., and Tavitian B. Labelled oligonucleotides as radiopharmaceuticals: pitfalls, problems and perspectives. Curr. Pharm. Des. 8 (2002) 1451-1466
165. Robertson K.W., Reeves R., Smith G., Keith W.N., Ozanne B.W., Cooke T.G., and Stanton P.D. Quantitative estimation of epidermal growth factor receptor and c-erbB-2 in human breast cancer. Cancer Res. 56 (1996) 3823-3830
166. Tian X., Aruva M.R., Qin W., Zhu W., Sauter E.R., Thakur M.L., and Wickstrom E. Noninvasive molecular imaging of MYC mRNA expression in human breast cancer xenografts with a [99mTc]peptide-peptide nucleic acid-peptide chimera. Bioconjug. Chem. 16 (2005) 70-79
167. Suzuki T., Wu D., Schlachetzki F., Li J.Y., Boado R.J., and Pardridge W.M. Imaging endogenous gene expression in brain cancer in vivo with 111In-peptide nucleic acid antisense radiopharmaceuticals and brain drug-targeting technology. J. Nucl. Med. 45 (2004) 1766-1775
168. Lesterhuis W.J., de Vries I.J., Adema G.J., and Punt C.J. Dendritic cell-based vaccines in cancer immunotherapy: an update on clinical and immunological results. Ann. Oncol. 15 Suppl. 4 (2004) iv145-iv151
169. Wang E., Panelli M.C., and Marincola F.M. Understanding the response to immunotherapy in humans. Springer Semin. Immunopathol. 27 (2005) 105-117
170. Knutson K.L., Almand B., Mankoff D.A., Schiffman K., and Disis M.L. Adoptive T-cell therapy for the treatment of solid tumours. Expert Opin. Biol. Ther. 2 (2002) 55-66
171. L.G. Lum, T cell-based immunotherapy for cancer: a virtual reality? C.A. Cancer J. Clin. 49 (1999), 74-100, 65.
172. Knutson K.L., and Disis M.L. IL-12 enhances the generation of tumour antigen-specific Th1 CD4 T cells during ex vivo expansion. Clin. Exp. Immunol. 135 (2004) 322-329
173. Maass G., Schmidt W., Berger M., Schilcher F., Koszik F., Schneeberger A., Stingl G., Birnstiel M.L., and Schweighoffer T. Priming of tumor-specific T cells in the draining lymph nodes after immunization with interleukin 2-secreting tumor cells: three consecutive stages may be required for successful tumor vaccination. Proc. Natl. Acad. Sci. U. S. A. 92 (1995) 5540-5544
174. Halin C., Rodrigo Mora J., Sumen C., and von Andrian U.H. In vivo imaging of lymphocyte trafficking. Annu. Rev. Cell Dev. Biol. 21 (2005) 581-603
175. Adonai N., Nguyen K.N., Walsh J., Iyer M., Toyokuni T., Phelps M.E., McCarthy T., McCarthy D.W., and Gambhir S.S. Ex vivo cell labeling with 64Cu-pyruvaldehyde-bis(N4-methylthiosemicarbazone) for imaging cell trafficking in mice with positron-emission tomography. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 3030-3035
176. Koike C., Oku N., Watanabe M., Tsukada H., Kakiuchi T., Irimura T., and Okada S. Real-time PET analysis of metastatic tumor cell trafficking in vivo and its relation to adhesion properties. Biochim. Biophys. Acta 1238 (1995) 99-106
177. Hardy J., Edinger M., Bachmann M.H., Negrin R.S., Fathman C.G., and Contag C.H. Bioluminescence imaging of lymphocyte trafficking in vivo. Exp. Hematol. 29 (2001) 1353-1360
178. Bulte J.W., Duncan I.D., and Frank J.A. In vivo magnetic resonance tracking of magnetically labeled cells after transplantation. J. Cereb. Blood Flow Metab. 22 (2002) 899-907
179. Bulte J.W., and Kraitchman D.L. Monitoring cell therapy using iron oxide MR contrast agents. Curr. Pharm. Biotechnol. 5 (2004) 567-584
180. Modo M., Hoehn M., and Bulte J.W. Cellular MR imaging. Mol. Imaging 4 (2005) 143-164
181. de Vries I.J., Lesterhuis W.J., Barentsz J.O., Verdijk P., van Krieken J.H., Boerman O.C., Oyen W.J., Bonenkamp J.J., Boezeman J.B., Adema G.J., Bulte J.W., Scheenen T.W., Punt C.J., Heerschap A., and Figdor C.G. Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy. Nat. Biotechnol. 23 (2005) 1407-1413
182. Kircher M.F., Allport J.R., Graves E.E., Love V., Josephson L., Lichtman A.H., and Weissleder R. In vivo high resolution three-dimensional imaging of antigen-specific cytotoxic T-lymphocyte trafficking to tumors. Cancer Res. 63 (2003) 6838-6846
183. Hu D.E., Kettunen M.I., and Brindle K.M. Monitoring T-lymphocyte trafficking in tumors undergoing immune rejection. Magn. Reson. Med. 54 (2005) 1473-1479
184. Hu D.E., Beauregard D.A., Bearchell M.C., Thomsen L.L., and Brindle K.M. Early detection of tumour immune-rejection using magnetic resonance imaging. Br. J. Cancer 88 (2003) 1135-1142
185. Marten A., Flieger D., Renoth S., Weineck S., Albers P., Compes M., Schottker B., Ziske C., Engelhart S., Hanfland P., Krizek L., Faber C., von Ruecker A., Muller S., Sauerbruch T., and Schmidt-Wolf I.G. Therapeutic vaccination against metastatic renal cell carcinoma by autologous dendritic cells: preclinical results and outcome of a first clinical phase I/II trial. Cancer Immunol. Immunother. 51 (2002) 637-644
186. Nestle F.O., Alijagic S., Gilliet M., Sun Y., Grabbe S., Dummer R., Burg G., and Schadendorf D. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med. 4 (1998) 328-332
187. Ehtesham M., Kabos P., Gutierrez M.A., Chung N.H., Griffith T.S., Black K.L., and Yu J.S. Induction of glioblastoma apoptosis using neural stem cell-mediated delivery of tumor necrosis factor-related apoptosis-inducing ligand. Cancer Res. 62 (2002) 7170-7174
188. Tang Y., Shah K., Messerli S.M., Snyder E., Breakefield X., and Weissleder R. In vivo tracking of neural progenitor cell migration to glioblastomas. Hum. Gene Ther. 14 (2003) 1247-1254
189. Zhang Z., Jiang Q., Jiang F., Ding G., Zhang R., Wang L., Zhang L., Robin A.M., Katakowski M., and Chopp M. In vivo magnetic resonance imaging tracks adult neural progenitor cell targeting of brain tumor. NeuroImage 23 (2004) 281-287
190. Cunningham C.H., Arai T., Yang P.C., McConnell M.V., Pauly J.M., and Conolly S.M. Positive contrast magnetic resonance imaging of cells labeled with magnetic nanoparticles. Magn. Reson. Med. 53 (2005) 999-1005
191. Seppenwoolde J.H., Viergever M.A., and Bakker C.J. Passive tracking exploiting local signal conservation: the white marker phenomenon. Magn. Reson. Med. 50 (2003) 784-790
192. Aime S., Cabella C., Colombatto S., Geninatti Crich S., Gianolio E., and Maggioni F. Insights into the use of paramagnetic Gd(III) complexes in MR-molecular imaging investigations. J. Magn. Reson. Imaging 16 (2002) 394-406
193. Ahrens E.T., Flores R., Xu H., and Morel P.A. In vivo imaging platform for tracking immunotherapeutic cells. Nat. Biotechnol. 23 (2005) 983-987
194. Seddon B.M., and Workman P. The role of functional and molecular imaging in cancer drug discovery and development. Br. J. Radiol. 76 Spec. No 2 (2003) S128-S138
195. Van Den Bossche B., and Van de Wiele C. Receptor imaging in oncology by means of nuclear medicine: current status. J. Clin. Oncol. 22 (2004) 3593-3607
196. Becker A., Hessenius C., Licha K., Ebert B., Sukowski U., Semmler W., Wiedenmann B., and Grotzinger C. Receptor-targeted optical imaging of tumors with near-infrared fluorescent ligands. Nat. Biotechnol. 19 (2001) 327-331
197. Bugaj J.E., Achilefu S., Dorshow R.B., and Rajagopalan R. Novel fluorescent contrast agents for optical imaging of in vivo tumors based on a receptor-targeted dye-peptide conjugate platform. J. Biomed. Opt. 6 (2001) 122-133
198. Artemov D., Bhujwalla Z.M., and Bulte J.W. Magnetic resonance imaging of cell surface receptors using targeted contrast agents. Curr. Pharm. Biotechnol. 5 (2004) 485-494
199. Artemov D., Mori N., Ravi R., and Bhujwalla Z.M. Magnetic resonance molecular imaging of the HER-2/neu receptor. Cancer Res. 63 (2003) 2723-2727
200. Smith C.J., Volkert W.A., and Hoffman T.J. Radiolabeled peptide conjugates for targeting of the bombesin receptor superfamily subtypes. Nucl. Med. Biol. 32 (2005) 733-740
201. Hilgenbrink A.R., and Low P.S. Folate receptor-mediated drug targeting: from therapeutics to diagnostics. J. Pharm. Sci. 94 (2005) 2135-2146
202. Montet X., Yuan H., Weissleder R., and Josephson L. Enzyme-based visualization of receptor-ligand binding in tissues. Lab. Invest. 86 (2006) 517-525
203. Winnard Jr. P., and Raman V. Real time non-invasive imaging of receptor-ligand interactions in vivo. J. Cell. Biochem. 90 (2003) 454-463
204. Teunissen J.J., Kwekkeboom D.J., and Krenning E.P. Staging and treatment of differentiated thyroid carcinoma with radiolabeled somatostatin analogs. Trends Endocrinol. Metab. 17 (2006) 19-25
205. Linden H.M., Stekhova S.A., Link J.M., Gralow J.R., Livingston R.B., Ellis G.K., Petra P.H., Peterson L.M., Schubert E.K., Dunnwald L.K., Krohn K.A., and Mankoff D.A. Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer. J. Clin. Oncol. 24 (2006) 2793-2799
206. Larson S.M., Morris M., Gunther I., Beattie B., Humm J.L., Akhurst T.A., Finn R.D., Erdi Y., Pentlow K., Dyke J., Squire O., Bornmann W., McCarthy T., Welch M., and Scher H. Tumor localization of 16beta-18F-fluoro-5alpha-dihydrotestosterone versus 18F-FDG in patients with progressive, metastatic prostate cancer. J. Nucl. Med. 45 (2004) 366-373
207. Murphy L.C., Dotzlaw H., Wong M.S., Miller T., Mrockowski B., Gong Y., and Murphy L.J. Epidermal growth factor: receptor and ligand expression in human breast cancer. Semin. Cancer Biol. 1 (1990) 305-315
208. Ke S., Wen X., Gurfinkel M., Charnsangavej C., Wallace S., Sevick-Muraca E.M., and Li C. Near-infrared optical imaging of epidermal growth factor receptor in breast cancer xenografts. Cancer Res. 63 (2003) 7870-7875
209. Ross J.S., Fletcher J.A., Bloom K.J., Linette G.P., Stec J., Symmans W.F., Pusztai L., and Hortobagyi G.N. Targeted therapy in breast cancer: the HER-2/neu gene and protein. Mol. Cell. Proteomics 3 (2004) 379-398
210. Orlova A., Magnusson M., Eriksson T.L., Nilsson M., Larsson B., Hoiden-Guthenberg I., Widstrom C., Carlsson J., Tolmachev V., Stahl S., and Nilsson F.Y. Tumor imaging using a picomolar affinity HER2 binding affibody molecule. Cancer Res. 66 (2006) 4339-4348
211. Kerr J.F., Wyllie A.H., and Currie A.R. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br. J. Cancer 26 (1972) 239-257
212. Kim R., Emi M., Tanabe K., Uchida Y., and Arihiro K. The role of apoptotic or nonapoptotic cell death in determining cellular response to anticancer treatment. Eur. J. Surg. Oncol. 32 (2006) 269-277
213. Corsten M.F., Hofstra L., Narula J., and Reutelingsperger C.P. Counting heads in the war against cancer: defining the role of annexin A5 imaging in cancer treatment and surveillance. Cancer Res. 66 (2006) 1255-1260
214. Buchholz T.A., Davis D.W., McConkey D.J., Symmans W.F., Valero V., Jhingran A., Tucker S.L., Pusztai L., Cristofanilli M., Esteva F.J., Hortobagyi G.N., and Sahin A.A. Chemotherapy-induced apoptosis and Bcl-2 levels correlate with breast cancer response to chemotherapy. Cancer J. 9 (2003) 33-41
215. Dubray B., Breton C., Delic J., Klijanienko J., Maciorowski Z., Vielh P., Fourquet A., Dumont J., Magdelenat H., and Cosset J.M. In vitro radiation-induced apoptosis and early response to low-dose radiotherapy in non-Hodgkin's lymphomas. Radiother. Oncol. 46 (1998) 185-191
216. Hakumaki J.M., and Brindle K.M. Techniques: visualizing apoptosis using nuclear magnetic resonance. Trends Pharmacol. Sci. 24 (2003) 146-149
217. Kettunen M.I., and Brindle K.M. Apoptosis detection using magnetic resonance imaging and spectroscopy. Prog. Nucl. Magn. Reson. Spectrosc. 47 (2005) 175-185
218. Blankenberg F.G., Katsikis P.D., Tait J.F., Davis R.E., Naumovski L., Ohtsuki K., Kopiwoda S., Abrams M.J., Darkes M., Robbins R.C., Maecker H.T., and Strauss H.W. In vivo detection and imaging of phosphatidylserine expression during programmed cell death. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 6349-6354
219. Bremer C., Ntziachristos V., and Weissleder R. Optical-based molecular imaging: contrast agents and potential medical applications. Eur. Radiol. 13 (2003) 231-243
220. Yagle K.J., Eary J.F., Tait J.F., Grierson J.R., Link J.M., Lewellen B., Gibson D.F., and Krohn K.A. Evaluation of 18F-annexin V as a PET imaging agent in an animal model of apoptosis. J. Nucl. Med. 46 (2005) 658-666
221. Adebodun F., and Post J.F. 31P NMR characterization of cellular metabolism during dexamethasone induced apoptosis in human leukemic cell lines. J. Cell. Physiol. 158 (1994) 180-186
222. Nunn A.V., Barnard M.L., Bhakoo K., Murray J., Chilvers E.J., and Bell J.D. Characterisation of secondary metabolites associated with neutrophil apoptosis. FEBS Lett. 392 (1996) 295-298
223. Anthony M.L., Zhao M., and Brindle K.M. Inhibition of phosphatidylcholine biosynthesis following induction of apoptosis in HL-60 cells. J. Biol. Chem. 274 (1999) 19686-19692
224. Williams S.N., Anthony M.L., and Brindle K.M. Induction of apoptosis in two mammalian cell lines results in increased levels of fructose-1,6-bisphosphate and CDP-choline as determined by 31P MRS. Magn. Reson. Med. 40 (1998) 411-420
225. Blankenberg F.G., Storrs R.W., Naumovski L., Goralski T., and Spielman D. Detection of apoptotic cell death by proton nuclear magnetic resonance spectroscopy. Blood 87 (1996) 1951-1956
226. Hakumaki J.M., Poptani H., Sandmair A.M., Yla-Herttuala S., and Kauppinen R.A. 1H MRS detects polyunsaturated fatty acid accumulation during gene therapy of glioma: implications for the in vivo detection of apoptosis. Nat. Med. 5 (1999) 1323-1327
227. Schmitz J.E., Kettunen M.I., Hu D.E., and Brindle K.M. 1H MRS-visible lipids accumulate during apoptosis of lymphoma cells in vitro and in vivo. Magn. Reson. Med. 54 (2005) 43-50
228. Chenevert T.L., Stegman L.D., Taylor J.M., Robertson P.L., Greenberg H.S., Rehemtulla A., and Ross B.D. Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors. J. Natl. Cancer Inst. 92 (2000) 2029-2036
229. Zhao M., Pipe J.G., Bonnett J., and Evelhoch J.L. Early detection of treatment response by diffusion-weighted 1H-NMR spectroscopy in a murine tumour in vivo. Br. J. Cancer 73 (1996) 61-64
230. Hamstra D.A., Chenevert T.L., Moffat B.A., Johnson T.D., Meyer C.R., Mukherji S.K., Quint D.J., Gebarski S.S., Fan X., Tsien C.I., Lawrence T.S., Junck L., Rehemtulla A., and Ross B.D. Evaluation of the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade glioma. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 16759-16764
231. Theilmann R.J., Borders R., Trouard T.P., Xia G., Outwater E., Ranger-Moore J., Gillies R.J., and Stopeck A. Changes in water mobility measured by diffusion MRI predict response of metastatic breast cancer to chemotherapy. Neoplasia 6 (2004) 831-837
232. Cryns V., and Yuan J. Proteases to die for. Genes Dev. 12 (1998) 1551-1570
233. Laxman B., Hall D.E., Bhojani M.S., Hamstra D.A., Chenevert T.L., Ross B.D., and Rehemtulla A. Noninvasive real-time imaging of apoptosis. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 16551-16555
234. Martin S.J., Reutelingsperger C.P., McGahon A.J., Rader J.A., van Schie R.C., LaFace D.M., and Green D.R. Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl. J. Exp. Med. 182 (1995) 1545-1556
235. Belhocine T., Steinmetz N., Hustinx R., Bartsch P., Jerusalem G., Seidel L., Rigo P., and Green A. Increased uptake of the apoptosis-imaging agent (99m)Tc recombinant human Annexin V in human tumors after one course of chemotherapy as a predictor of tumor response and patient prognosis. Clin. Cancer Res. 8 (2002) 2766-2774
236. Narula J., Acio E.R., Narula N., Samuels L.E., Fyfe B., Wood D., Fitzpatrick J.M., Raghunath P.N., Tomaszewski J.E., Kelly C., Steinmetz N., Green A., Tait J.F., Leppo J., Blankenberg F.G., Jain D., and Strauss H.W. Annexin-V imaging for noninvasive detection of cardiac allograft rejection. Nat. Med. 7 (2001) 1347-1352
237. Haas R.L., de Jong D., Valdes Olmos R.A., Hoefnagel C.A., van den Heuvel I., Zerp S.F., Bartelink H., and Verheij M. In vivo imaging of radiation-induced apoptosis in follicular lymphoma patients. Int. J. Radiat. Oncol. Biol. Phys. 59 (2004) 782-787
238. Kartachova M., Haas R.L., Olmos R.A., Hoebers F.J., van Zandwijk N., and Verheij M. In vivo imaging of apoptosis by 99mTc-Annexin V scintigraphy: visual analysis in relation to treatment response. Radiother. Oncol. 72 (2004) 333-339
239. Boersma H.H., Kietselaer B.L., Stolk L.M., Bennaghmouch A., Hofstra L., Narula J., Heidendal G.A., and Reutelingsperger C.P. Past, present, and future of annexin A5: from protein discovery to clinical applications. J. Nucl. Med. 46 (2005) 2035-2050
240. Choy G., Choyke P., and Libutti S.K. Current advances in molecular imaging: noninvasive in vivo bioluminescent and fluorescent optical imaging in cancer research. Mol. Imaging 2 (2003) 303-312
241. Petrovsky A., Schellenberger E., Josephson L., Weissleder R., and Bogdanov Jr. A. Near-infrared fluorescent imaging of tumor apoptosis. Cancer Res. 63 (2003) 1936-1942
242. Zhao M., Beauregard D.A., Loizou L., Davletov B., and Brindle K.M. Non-invasive detection of apoptosis using magnetic resonance imaging and a targeted contrast agent. Nat. Med. 7 (2001) 1241-1244
243. Schellenberger E.A., Bogdanov Jr. A., Hogemann D., Tait J., Weissleder R., and Josephson L. Annexin V-CLIO: a nanoparticle for detecting apoptosis by MRI. Mol. Imaging 1 (2002) 102-107
244. Jung H.I., Kettunen M.I., Davletov B., and Brindle K.M. Detection of apoptosis using the C2A domain of synaptotagmin I. Bioconjug. Chem. 15 (2004) 983-987
245. Krishnan A., Neves A., Kettunen M., Hu D.-E., de Backer M., and Brindle K.M. Development of gadolinium based contrast agents to detect tumor apoptosis in vivo using MRI. Proc. Int. Soc. Magn. Reson. Med. 14 (2006) 1838
246. van Tilborg G.A., Mulder W.J., Deckers N., Storm G., Reutelingsperger C.P., Strijkers G.J., and Nicolay K. Annexin A5-functionalized bimodal lipid-based contrast agents for the detection of apoptosis. Bioconjug. Chem. 17 (2006) 741-749
247. Esfand R., and Tomalia D.A. Poly(amidoamine) (PAMAM) dendrimers: from biomimicry to drug delivery and biomedical applications. Drug Discovery Today 6 (2001) 427-436
248. Sato N., Kobayashi H., Saga T., Nakamoto Y., Ishimori T., Togayashi K., Fujibayashi Y., Konishi J., and Brechbiel M.W. Tumor targeting and imaging of intraperitoneal tumors by use of antisense oligo-DNA complexed with dendrimers and/or avidin in mice. Clin. Cancer Res. 7 (2001) 3606-3612
249. Neves A.A., Krishnan A., Kettunen M., Hu D.-E., de Backer M., and Brindle K.M. Development of avidin-based positive contrast agents to detect tumor apoptosis using MRI. Proc. Intl. Soc. Mag. Reson. Med. 14 (2006) 1844
250. Hutchings M., Eigtved A.I., and Specht L. FDG-PET in the clinical management of Hodgkin lymphoma. Crit. Rev. Oncol./Hematol. 52 (2004) 19-32
251. Luker G.D., Flagg T.P., Sha Q., Luker K.E., Pica C.M., Nichols C.G., and Piwnica-Worms D. MDR1 P-glycoprotein reduces influx of substrates without affecting membrane potential. J. Biol. Chem. 276 (2001) 49053-49060
252. Sharma V. Radiopharmaceuticals for assessment of multidrug resistance P-glycoprotein-mediated drug transport activity. Bioconjug. Chem. 15 (2004) 1464-1474
253. Agrawal M., Abraham J., Balis F.M., Edgerly M., Stein W.D., Bates S., Fojo T., and Chen C.C. Increased 99mTc-sestamibi accumulation in normal liver and drug-resistant tumors after the administration of the glycoprotein inhibitor, XR9576. Clin. Cancer Res. 9 (2003) 650-656
254. West C.M., Jones T., and Price P. The potential of positron-emission tomography to study anticancer-drug resistance. Nat. Rev., Cancer 4 (2004) 457-469
255. Kelloff G.J., and Sigman C.C. New science-based endpoints to accelerate oncology drug development. Eur. J. Cancer 41 (2005) 491-501
256. U.S. Department of Health and Human Services Food and Drug Administration, Innovation/Stagnation. Challenge and Opportunity on the Critical Path to New Medical Products (2004), 1-38.
257. Lappin G., and Garner R.C. Big physics, small doses: the use of AMS and PET in human microdosing of development drugs. Nat. Rev., Drug Discov. 2 (2003) 233-240